This Is MS Multiple Sclerosis Knowledge & Support Community

Treatment with natalizumab (Tysabri, Biogen Idec and Elan) leads to improved language processing and retrieval of newly learned verbal material in patients with multiple sclerosis (MS).

The researchers compared the effects of natalizumab with treatment with other disease-modifying therapies in patients with MS. The study included 46 patients taking natalizumab (mean ± SD age, 43.2 ± 9.1 years; mean ± SD years of education, 15.1 ± 2.5 years; 76% female; mean ± SD intertest interval, 14.9 ± 3.9 months; mean ± SD Expanded Disability Status Scale [EDSS] score, 3.8 ± 2.2; and disease duration <5 years, 9%; 5 – 10 years, 50%; and >10 years, 41%).... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768

squiffy2 wrote:

Treatment with natalizumab (Tysabri, Biogen Idec and Elan) leads to improved language processing and retrieval of newly learned verbal material in patients with multiple sclerosis (MS).

Geez, the results sure don't cast a positive note on the CRAB drugs which we were told for years benefited MS patients!

I'm not surprised that Biogen/Elan have released this kind of study using a method that appears to be questioned by some experts. The marketing share of Tysabri is way below expectations and they need to do something to improve this.

Harry